Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b
Open-Label Multi-Center Single Arm Clinical Trial to Study the Efficacy and Safety of the Elbasvir/ Grazoprevir 50/100 mg Fixed Dose Combination Once Daily in Patients With Chronic HCV GT1b Infection Associated With Metabolic Syndrome
Sponsor: Institute Of Cardiology & Internal Diseases, Kazakhstan
Listed as NCT03222167, this PHASE3 trial focuses on Chronic Hepatitis C Genotype 1B and Cirrhoses, Liver and remains ongoing. Sponsored by Institute Of Cardiology & Internal Diseases, Kazakhstan, it has been updated 8 times since 2017, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jun 2022 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Jan 2021 — Jun 2022 [monthly]
Unknown Status PHASE3
-
Sep 2019 — Jan 2021 [monthly]
Unknown Status PHASE3
Status: Not Yet Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — Sep 2019 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE3
-
Aug 2017 — Sep 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Institute Of Cardiology & Internal Diseases, Kazakhstan
- Merck Sharp & Dohme LLC
- Synergy Research Group
For direct contact, visit the study record on ClinicalTrials.gov .